Gene set variation analysis of the four different cohorts identified a preponderance of G2M cell cycle, Myc-driven biology and DNA repair signatures in the ID subtype, suggesting that chemotherapies alone could provide the best overall clinical benefit to patients with this tumor subtype. The gene discussed is MYC; the disease is neoplasm.